SelectQuote (SLQT) Earnings Date & Reports

Key Takeaways

• SelectQuote, Inc. (SLQT) reported first-quarter fiscal 2027 revenue of $280.0 million, a decline of about 15% from $328.8 million a year earlier, but slightly above the consensus estimate of roughly $278 million.
• The company's GAAP net loss narrowed to $20.3 million from $30.5 million, while diluted loss per share improved to $0.21 from $0.26 in the prior-year quarter.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization, a measure of core operating profitability) improved by $15 million year over year to a loss of $17.0 million.
• Management reaffirmed full-year fiscal 2027 guidance for revenue of $1.35 billion to $1.45 billion and at least $60 million of operating cash flow.
• Profitability per SelectRx member rose 60% year over year, reflecting efficiency gains from technology and artificial intelligence (AI) investments even as revenue softened.
• For additional context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for deeper analysis.
• To uncover automated trading ideas built around these market dynamics, explore Trending AI Robots.

Earnings Context and Why It Matters

SelectQuote's first fiscal quarter is historically a seasonal investment period ahead of the Medicare Annual Enrollment Period (AEP), the fall window when seniors can switch Medicare Advantage and prescription drug plans. This quarter's report matters because it reveals how the company is balancing two competing forces: a deliberately smaller senior agent force and revenue pressure from the Inflation Reduction Act (IRA), a federal law that lowered some prescription drug pricing, against a push for stronger profitability and cash flow. With the stock trading at low levels and a reverse stock split vote scheduled for its November 10 annual meeting, investors are closely watching whether SelectQuote's margin and cash-flow improvements can outpace a shrinking top line.

Reported Results

For the first quarter of fiscal 2027 ended September 30, 2026, SelectQuote reported consolidated revenue of $280.0 million, down roughly 15% from $328.8 million in the prior-year period. The company attributed the decline to a smaller senior agent force and the impact of the Inflation Reduction Act on its Healthcare Services segment.

Net loss narrowed to $20.3 million from $30.5 million a year earlier, and diluted loss per share from continuing operations improved to $0.21 from $0.26. Adjusted EBITDA improved $15 million year over year to a loss of $17.0 million, and cash used in operations declined to $17.2 million from $21.6 million. Revenue edged past the approximately $278 million consensus estimate, while the per-share loss came in ahead of expectations.

By segment, Senior revenue fell 14% to $50.8 million, while its adjusted EBITDA loss improved to $12.3 million from $21.0 million. Healthcare Services revenue declined 16% to $186.3 million, but adjusted EBITDA rose 56% to $11.2 million, and profitability per SelectRx member climbed 60% to $107.6. The Life segment generated $42.8 million in revenue with adjusted EBITDA of $7.3 million, as its margin expanded to 17% from 12%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors following earnings-driven moves can use it to monitor companies like SelectQuote and identify emerging opportunities across sectors.

Market Reaction and Investor Sentiment

Shares rallied sharply following the release, as investors rewarded the year-over-year improvement in adjusted EBITDA and operating cash flow despite the revenue decline. The results reinforced the view that SelectQuote is prioritizing profitability and cash generation over volume, a strategy that has drawn scrutiny given the shrinking top line. Still, sentiment remains cautious around the company's balance sheet and listing status, with a reverse stock split proposal set for a shareholder vote on November 10. The upbeat margin story, combined with early signs of strong customer engagement heading into AEP, appeared to offset concerns about lower Medicare Advantage policy volumes for now.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on how SelectQuote performs during the Medicare AEP and Open Enrollment Period, which drive the bulk of its Senior and SelectRx revenue in the second and third fiscal quarters. Management described the upcoming season as another dynamic recovery year for Medicare Advantage, citing elevated plan terminations and benefit changes that could increase demand for its agent-led model.

Key factors to watch include approved Medicare Advantage policy volumes, the lifetime value (LTV) of commissions per approved policy, and the recapture rate for beneficiaries whose plans were terminated. In Healthcare Services, the ramp of the new Olathe, Kansas distribution facility and the in-house pharmacy management system could support the company's target of roughly doubling segment margins in fiscal 2027.

On the balance sheet, investors should monitor operating cash flow progress toward the $60 million-plus target, along with any updates on the preferred dividend and the outcome of the reverse stock split vote. The company's own guidance still implies continued revenue shrinkage, so the central question remains whether efficiency and cash-flow gains can sustain the stock's momentum without a return to top-line growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations